NASDAQ •
Healthcare •
Biotechnology •
Quote as of 08/14/2026
Company Profile
IndustryBiotechnology
SectorHealthcare
ExchangeNASDAQ
Market Capitalization6,827.97 mln
Float64.44 mln
Earnings Date11/12/2026
Piotroski F-Score
3
/ 9
Below average
Beneish M-Score
1.04
Highly suspicious
1-Year Forecast
91.08
Attractive
Relative Strength
68
/ 100
Outperforming
Debt / Equity
0.01
Debt-free
ROE
-26.51
Deeply negative
Business Description
CG Oncology is a clinical-stage biopharmaceutical company based in Irvine, California, focused on developing a single investigational treatment called cretostimogene grenadenorepvec for people with bladder cancer. The therapy works by stimulating the immune system and is currently being tested across multiple advanced clinical trials targeting various forms of non-muscle-invasive bladder cancer, including cases where standard BCG treatment has not worked. Founded in 2010 and formerly known as Cold Genesys Inc., the company is working to establish cretostimogene as both a standalone treatment and a potential option for patients at different stages and risk levels of the disease.